MICROBIOME MARKERS AND THERAPIES FOR AUTISM SPECTRUM DISORDERS

摘要

The present disclosure provides for characterization of normal flora and identifying biomarkers in the gut of healthy, neruotypical subjects. Aspect of the disclosure provide for the characterization of the gut microbiome in ADS subjects, characterized by reduced richness and significant loss of the ‘Prevotella-like enterotype’ compared to neurotypical subjects. The relative abundance of genera Prevotella, Coprococcus, Prevotellaceae and Veillonellaceae are significantly lower in autistic children than in neurotypical children. Further, Prevotella, is one of the three main classifiers for the human enterotypes, along with Bacteroides and Ruminococcus. These three core genera are among main contributors in the principle component analysis. ‘Prevotella-like enterotype’ was absent in the autistic group, while neurotypical samples showed an even distribution among the three enterotypes. The present disclosure provides for an understanding the association between gut microbiota, health, and disease states, and provides for potential diagnostic and therapeutic targets.

主权项

1. An assay comprising:
(a) subjecting nucleic acid extracted from a test sample of a human subject to a genotyping assay that detects at least one of Prevotella, Coprococcus, Prevotellaceae, or Veillonellaceae bacteria, the test sample including microbiota from a gut of the subject; (b) determining a relative abundance of the at least one of Prevotella, Coprococcus, Prevotellaceae, or Veillonellaceae bacteria that is below a predetermined abundance; and (c) selecting, when the relative abundance is below the predetermined abundance, a treatment regimen that comprises at least one of:
(i) modifying microbiota of the gut of the subject using at least one of a prebiotic, probiotic, or pharmaceutical, or(ii) applying a therapeutic regimen for treating autism spectrum disorders.